The estimated Net Worth of Stephen S. Yoder is at least $1.7 Milión dollars as of 13 June 2016. Mr. Yoder owns over 6,000 units of Pieris Pharmaceuticals Inc stock worth over $104,940 and over the last 9 years he sold PIRS stock worth over $0. In addition, he makes $1,593,600 as President, Chief Executive Officer a Director at Pieris Pharmaceuticals Inc.
Stephen has made over 2 trades of the Pieris Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of PIRS stock worth $10,080 on 13 June 2016.
The largest trade he's ever made was buying 6,000 units of Pieris Pharmaceuticals Inc stock on 13 June 2016 worth over $10,080. On average, Stephen trades about 1,200 units every 0 days since 2016. As of 13 June 2016 he still owns at least 6,000 units of Pieris Pharmaceuticals Inc stock.
You can see the complete history of Mr. Yoder stock trades at the bottom of the page.
Stephen S. Yoder is President, Chief Executive Officer, Director of the Company. Mr. Yoder joined Pieris Pharmaceuticals GmbH as Chief Executive Officer in January 2010, and was appointed to the Board of Directors of Pieris and became Chief Executive Officer and President in 2014. From July 2003 to December 2009, he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. From September 1999 to June 2003, he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School. As an attorney, he is licensed to practice before the United States Patent and Trademark Office and in the jurisdictions of Maryland and Washington, D.C.
As the President, Chief Executive Officer a Director of Pieris Pharmaceuticals Inc, the total compensation of Stephen Yoder at Pieris Pharmaceuticals Inc is $1,593,600. There are no executives at Pieris Pharmaceuticals Inc getting paid more.
Stephen Yoder is 44, he's been the President, Chief Executive Officer a Director of Pieris Pharmaceuticals Inc since 2014. There are 14 older and 3 younger executives at Pieris Pharmaceuticals Inc. The oldest executive at Pieris Pharmaceuticals Inc is Peter Kiener, 68, who is the Independent Director.
Stephen's mailing address filed with the SEC is C/O PIERIS PHARMACEUTICALS, INC., 225 FRANKLIN STREET, 26TH FLOOR, BOSTON, MA, 02110.
Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over $24,745,707 worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth $3,376,410 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Advisors Llc Orbi Med Capit... a Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of $4,572,148. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth $92,340.
pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche
Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include: